» Articles » PMID: 17391319

A Three-decade Analysis of 3,911 Small Intestinal Neuroendocrine Tumors: the Rapid Pace of No Progress

Overview
Specialty Gastroenterology
Date 2007 Mar 30
PMID 17391319
Citations 61
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Small intestinal neuroendocrine tumors (SI-NETs) are the most common gastrointestinal neuroendocrine tumor, but their natural history and outcome remain poorly defined, which hinders both the prediction of disease progression and appropriate therapeutic options. We examined patterns, incidence, prognosis, and outcomes of these tumors over a 30-yr period.

Methods: Data were extracted from the NCI's SEER registry (1973-2002). Incidence rates, distribution, and 5-yr survival rates were analyzed and adjusted (U.S. decennial census data).

Results: Of the 18,641 NETs, 3,911 (21.0%) were SI-NETs, of which 1,953 (49.6%) were ileal. Since 1973, both SI-NET and its ileal variant have increased annually by 3.8% and 2.1%, respectively. Ileal tumors, as a percentage of SI tumors, have increased from 52% to 63.6%. The age-adjusted incidence of ileal, small intestinal, and digestive system NETs has increased 225%, 460%, and 720% over 30 yr. Ileal tumors have specifically increased in prevalence in white (274%) and black (500%) men and women (213% and 286%, respectively); an overall increase of fourfold in blacks and 2.4-fold in whites. Although 83.3% of SI-NETs were staged, 83.7% were histologically ungraded. Five-year survival rates for SI-NETs were 62.6 +/- 1% (all stages), 73.8% (localized), 72% (regional), and 43.2% (distant). These have not significantly altered since 1973 (P= 0.11).

Conclusions: SI-NETs have increased, particularly in men and in the black population, which may be due to in vivo changes, increased clinical and pathological awareness, or increased detection of tumors. SI-NETs are malignant, diagnosed late, and survival rates have remained unchanged over 30 yr.

Citing Articles

Surgical Management of Gastroenteropancreatic Neuroendocrine Tumors.

Kenney L, Hughes M Cancers (Basel). 2025; 17(3).

PMID: 39941746 PMC: 11816225. DOI: 10.3390/cancers17030377.


Epidemiological characteristics of neuroendocrine neoplasms in Beijing: a population-based retrospective study.

Chi Y, Liu S, Zhang J, Li H, Yang L, Zhang X BMC Public Health. 2024; 24(1):1396.

PMID: 38789981 PMC: 11127419. DOI: 10.1186/s12889-024-18845-8.


Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That?.

Uccella S Endocr Pathol. 2024; 35(2):91-106.

PMID: 38470548 PMC: 11176254. DOI: 10.1007/s12022-024-09807-2.


Surgery as a Principle and Technical Consideration for Primary Tumor Resection of Small Bowel Neuroendocrine Tumors.

Soreide K, Stattner S, Hallet J Ann Surg Oncol. 2023; 31(2):1125-1137.

PMID: 38006527 PMC: 10761444. DOI: 10.1245/s10434-023-14610-0.


Small Bowel Neuroendocrine Tumors-10-Year Experience of the Ottawa Hospital (TOH).

Alfagih A, AlJassim A, Alqahtani N, Vickers M, Goodwin R, Asmis T Curr Oncol. 2023; 30(8):7508-7519.

PMID: 37623025 PMC: 10453717. DOI: 10.3390/curroncol30080544.